Ironwood Financial llc Sells 760 Shares of GSK plc (NYSE:GSK)

Ironwood Financial llc decreased its holdings in shares of GSK plc (NYSE:GSK) by 13.2% during the third quarter, HoldingsChannel reports. The fund owned 4,985 shares of the pharmaceutical company’s stock after selling 760 shares during the quarter. Ironwood Financial llc’s holdings in GSK were worth $204,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Register Financial Advisors LLC bought a new position in shares of GSK in the first quarter worth $31,000. Ashton Thomas Private Wealth LLC bought a new position in GSK in the 2nd quarter worth about $37,000. PrairieView Partners LLC purchased a new stake in shares of GSK in the 2nd quarter valued at about $47,000. Triad Wealth Partners LLC bought a new stake in shares of GSK during the 2nd quarter valued at about $49,000. Finally, Concord Wealth Partners grew its holdings in shares of GSK by 69.7% during the first quarter. Concord Wealth Partners now owns 1,436 shares of the pharmaceutical company’s stock worth $62,000 after purchasing an additional 590 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 0.6 %

GSK stock traded down $0.25 during mid-day trading on Thursday, reaching $38.96. The stock had a trading volume of 257,103 shares, compared to its average volume of 3,716,930. GSK plc has a one year low of $33.67 and a one year high of $45.92. The company has a 50-day moving average price of $41.50 and a two-hundred day moving average price of $41.30. The company has a market capitalization of $80.74 billion, a price-to-earnings ratio of 14.21, a PEG ratio of 1.30 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The business had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. On average, analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were given a $0.3843 dividend. This represents a $1.54 annualized dividend and a yield of 3.95%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, August 16th. GSK’s dividend payout ratio (DPR) is presently 55.80%.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of research analyst reports. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Jefferies Financial Group increased their target price on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Citigroup upgraded GSK to a “strong-buy” rating in a research report on Monday, June 24th. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $50.00.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.00% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.